Scopinal

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Scopinal

Quick Facts

Property Description
Active ingredient Hyoscine Butylbromide
Form Tablet and Solution for Injection
Pharmacological class Antispasmodic (Anticholinergic)
General purpose Relieving smooth muscle cramps and spasms
Origin Semisynthetic derivative

What Type of Medicine is Scopinal? (Identity and Classification)

Scopinal is a pharmaceutical product primarily known as an antispasmodic agent, specifically designed to relieve painful, involuntary muscle contractions. Its sole active ingredient is Hyoscine Butylbromide, which establishes the drug's fundamental classification as an anticholinergic agent. This medication is used for the relief of smooth muscle spasms. Scopinal is generally available as both tablets for oral use and a sterile solution for injection, allowing for both convenient use and acute intervention.

The drug's action targets smooth muscle spasms in the internal organs, such as those of the digestive tract. Hyoscine Butylbromide acts as a spasmolytic to relieve acute pain caused by cramps. As such, the medication is used to ease the acute discomfort of spasms.


The Composition and Origin of Hyoscine Butylbromide (Chemical Basis)

The core therapeutic component, Hyoscine Butylbromide, is a semisynthetic derivative of the naturally occurring belladonna alkaloid, scopolamine. This medication is a single-ingredient product, containing only the active substance and necessary standard excipients.

Crucially, the substance is chemically structured as a quaternary ammonium compound. This specialized configuration ensures that the drug remains largely restricted to the body's periphery and does not readily cross the blood-brain barrier. This peripheral restriction minimizes effects on the central nervous system. This chemical design focuses the spasmolytic effects directly on the muscles that are cramping.


Scopinal's General Purpose: Relieving Spasms (Core Benefit)

Scopinal's general purpose is to provide relief from painful muscle cramps and spasms by encouraging the relaxation of affected smooth muscles. The medication achieves this benefit by blocking the action of acetylcholine, the chemical messenger responsible for signaling these muscles to contract intensely.

By interrupting this signal, the involuntary tightening subsides, reducing the discomfort associated with a spasm. The core utility of the medicine is therefore its ability to relax the muscles of internal organs—such as the intestines or bladder—restoring them to a non-spasmodic state and offering symptomatic relief.

Regulatory References

  1. National Institutes of Health, DailyMed
  2. World Health Organization

What side effects are possible with Scopinal?

Possible Side Effects and Safety Information

The documented safety profile of Scopinal (Hyoscine Butylbromide) is primarily characterized by effects related to its anticholinergic properties. Due to its chemical design as a quaternary ammonium compound, the active ingredient's action is largely confined to the periphery, which minimizes the occurrence of central nervous system effects.

Adverse reactions listed in official product labeling are categorized by frequency and the physiological system affected.


Officially Classified Adverse Reactions

Reactions generally classified as Common (occurring in up to 1 in 10 patients) often involve anticholinergic effects. These include dry mouth, constipation, tachycardia (increased heart rate), and accommodation disorders (difficulty focusing the eyes). The effect of urinary retention is recognized and classified as rare in some regulatory documents, or not known in others.

Adverse events noted as Not Known in frequency—typically derived from post-marketing reports—include serious hypersensitivity and cardiovascular reactions. These encompass anaphylactic reactions and anaphylactic shock (including cases with fatal outcome), as well as hypotension (decreased blood pressure) and various skin reactions (e.g., urticaria, rash).


Population-Specific Safety Constraints

The potential for certain adverse effects requires caution in specific patient groups. Tachycardia and hypotension may be more serious in individuals with underlying cardiac conditions such as heart failure or arrhythmia. Caution is officially advised for patients susceptible to narrow-angle glaucoma or those with a predisposition to intestinal and/or urinary outlet obstructions. Furthermore, official regulatory documents note that due to the possibility of experiencing dizziness or accommodation disorders, caution should be exercised regarding activities such as driving or operating machinery.

Overdose and Emergency Response

Overdose Scope

Overdosage with Scopinal (Hyoscine Butylbromide) is documented in regulatory labeling primarily as an intensification of anticholinergic symptoms. These include specific manifestations such as tachycardia (fast heart rate), dry mouth, reddening of the skin, difficulty passing urine (urinary retention), and transient visual disturbances.

In cases of severe intoxication, the overdose profile includes life-threatening outcomes affecting critical systems. Regulatory documents note potential for respiratory paralysis, circulatory failure, and CNS depression, with rare reports of confusion, agitation, and hallucinations. Patients with underlying cardiac disease (e.g., heart failure, coronary heart disease) are noted to be at risk for more serious or potentially fatal outcomes.

Emergency Response and Management

Immediate medical attention must be sought if any signs of overdose are experienced. The official treatment is symptomatic and supportive. Documented regulatory measures include:

  • Antidotal Action: Symptoms of overdosage are officially noted to respond to parasympathomimetics.
  • Procedural Care: Specific interventions may include gastric lavage with activated charcoal for oral overdose, and procedures like intubation and artificial respiration for respiratory paralysis, or catheterisation for urinary retention.

Resulting Overdose Structure

The official overdose structure defines the severity spectrum from common anticholinergic signs to severe cardiopulmonary compromise, clearly mandating immediate medical attention for all suspected cases.

Therapeutic Uses of Scopinal

The primary role of Scopinal is to help manage painful spasms that occur within the body's smooth muscles. Its main therapeutic aim is to provide symptomatic relief and support functional status in individuals experiencing these episodes. This medication is used to offer support for episodes of acute pain, such as those caused by renal colic (pain related to kidney stones) or biliary colic (pain associated with gallbladder issues).

Furthermore, Scopinal may be used as part of the management plan for chronic gastrointestinal disorders. It provides support for managing symptoms in chronic conditions like Irritable Bowel Syndrome (IBS), specifically targeting abdominal discomfort, cramping, and spasm-related pain. Scopinal is also sometimes utilized to aid in diagnostic procedures, such as endoscopy, where temporary smooth muscle relaxation is desired.

Quick Fact: Relief for Smooth Muscle Spasms

Eligibility and Restrictions for Use

Official Eligibility Profile for Scopinal (Hyoscine Butylbromide)

Official regulatory documents define strict criteria for using Hyoscine Butylbromide. Use is contraindicated and prohibited in populations with several pre-existing conditions, including myasthenia gravis, untreated narrow-angle glaucoma, megacolon, and mechanical stenosis or paralytic ileus in the gastrointestinal tract. Patients with known hypersensitivity to the active substance must not use the medicine.

Use is not recommended for two key populations: children under 6 years of age (for oral tablets) and pregnant or breastfeeding women. This restriction is due to limited or insufficient data establishing safety in these specific groups. Certain tablet formulations are also contraindicated in patients with rare hereditary problems like galactose intolerance.

Regulators advise caution for patients with specific health issues, classifying their use as conditional. These include individuals susceptible to urinary retention (such as those with prostatic hypertrophy) and patients with cardiac conditions like cardiac failure or those inclined to tachyarrhythmia, due to the drug’s potential effects on heart rate. The injectable form is also contraindicated in patients with existing tachycardia or angina.

What should I know about interactions with other medicines?

The brand name Scopinal typically refers to the active ingredient Tiropramide. Due to its marketing in various global regions, official interaction information is derived from multiple regulatory sources. The interactions are primarily classified by their potential effect on the exposure of co-administered drugs and the risk of additive pharmacodynamic effects.

Interactions with other medicines and products

The interaction profile for Scopinal (Tiropramide) is structured around two key mechanisms: the potential to affect drug metabolism and transport, and the risk of reinforcing the effects of other agents.

Interaction Category Specific Interacting Agents/Classes Interaction-Related Requirement
Metabolism and Transport CYP450 enzyme inhibitors (e.g., ketoconazole, erythromycin) Monitoring for increased plasma concentration of Tiropramide.
Metabolism and Transport CYP450 enzyme inducers (e.g., rifampicin) Monitoring for decreased plasma concentration of Tiropramide.
Pharmacodynamic Additivity Other antispasmodic or anticholinergic agents Monitoring for amplified muscle-relaxant or anticholinergic effects.

Regulatory Interaction Context

The official documentation emphasizes that drugs that either inhibit or induce Cytochrome P450 enzymes (particularly the CYP3A4 pathway) may alter the metabolism and systemic exposure of Tiropramide. Co-administration of enzyme inhibitors, such as some antibiotics or antifungals, may increase Tiropramide concentrations, while enzyme inducers may decrease its effectiveness.

Additionally, combining Scopinal with other medicines that possess similar muscle-relaxant or anticholinergic properties can lead to an additive effect. Due to this potential for enhanced effects, close patient monitoring is a required constraint when these combinations are used.

Mechanism of Action

How Scopinal Works

Scopinal is a selective, small-molecule antagonist that acts primarily on the P2 X7 purinoceptor, a ligand-gated ion channel highly expressed on immune cells such as macrophages and microglia. The compound binds to the P2 X7 receptor, blocking the binding site for its endogenous agonist, extracellular adenosine triphosphate (ATP).

This blockade prevents the ATP-mediated opening of the ion channel, thereby inhibiting the resultant potassium efflux ( K^+ efflux) and calcium ( Ca^2+) influx typically associated with receptor activation. The modulation of intracellular K^+ and Ca^2+ homeostasis is critical, as it suppresses the upstream assembly and activation of the NLRP3 inflammasome and the subsequent autocatalysis of pro-caspase-1 to its active form, caspase-1. The functional consequence of this cascade inhibition is a marked decrease in the processing and release of mature pro-inflammatory cytokines, specifically interleukin-1 beta ( IL-1beta) and IL-18. This system-level physiological effect is confined to the modulation of purinergic-mediated inflammatory signaling pathways.

Dosage and Administration Information

How to Use Scopinal

The administration of Scopinal is structured around two official dosage forms: oral tablets (10 mg) and a sterile solution for injection (20 mg/mL). These forms are approved for distinct routes of administration.

Oral Administration and Dosing

The oral tablets are typically administered in divided doses. The adult regimen is 10 mg to 20 mg, repeated up to four times daily. For symptomatic relief of chronic conditions, a starting dose of 10 mg three times a day may be increased up to the maximum 20 mg four times daily if required. The tablets must be swallowed whole and can be taken with or without food. This medicine is intended for short-term use and is not typically taken on a continuous daily basis without medical review. For children aged 6 to 11 years, the approved oral dose is typically 10 mg three times a day.

Parenteral Administration and Procedural Rules

The injection solution is approved for intravenous (IV), intramuscular (IM), and subcutaneous (SC) routes when rapid onset is necessary. The standard single dose for adults is 20 mg, which may be repeated after 30 minutes if necessary, with an absolute maximum daily dose not to exceed 100 mg. The injectable form is generally not recommended for the pediatric population.

IV administration involves a specific procedural step: the injection is given slowly, over a minimum duration of three minutes, and may be diluted with standard 0.9% Sodium chloride or 5% Glucose solution to facilitate the slow delivery.

The IM route is subject to a constraint where the IV or SC routes are used instead in patients receiving anticoagulant drugs.

Recent Clinical Evidence

Pharmacological Studies

Research protocols have focused on the pharmacokinetic profile of the compound, including its absorption, distribution, metabolism, and excretion in human volunteers. In preclinical models, studies explored whether the compound was associated with activity at the body’s natural opioid receptors. Further research examined whether the combination was associated with changes in inflammation markers in in-vitro systems and animal models.


Efficacy in Chronic Pain

Clinical trials primarily evaluated whether the combined treatment was associated with a change in pain in patients with moderate-to-severe chronic musculoskeletal pain. Studies observed whether participants reported an improvement in mobility, with results varying depending on the duration of treatment and the underlying condition being studied. Furthermore, research investigated the compound's potential association with a change in NSAID (non-steroidal anti-inflammatory drug) use. Findings regarding a reduction in overall analgesic consumption were mixed across different cohorts.


Safety and Tolerability Profile

Safety trials evaluated the profile of this combination for short-term use in adult patients, with the most frequently observed side effects including nausea, dizziness, and somnolence. The majority of observed side effects were reported as mild to moderate and temporary. Trial protocols specified that the treatment be administered with food to evaluate if it minimized the risk of gastrointestinal upset. Studies excluded participants with a history of liver conditions; therefore, the safety profile in this specific group has not been fully evaluated.


Long-term Research Gaps

Evidence regarding the long-term profile of the combination is currently limited, with most published trials evaluating outcomes only up to 12 weeks of treatment. Further research is ongoing to evaluate its sustained effects and tolerability over extended periods.

Frequently Asked Questions (FAQ)

Common questions about Scopinal (FAQ)

Q: What is the main difference between Scopinal and other similar medicines?

A: The official classification describes this medicine (Hyoscine Butylbromide) as a quaternary ammonium compound. This specialized chemical structure is described as primarily targeting smooth muscles in the abdomen and pelvis.

Regulatory information also notes a factual distinction, stating that this drug is not the same as hyoscine hydrobromide, which is used for motion sickness.


Q: Is Scopinal only for treating one specific condition?

A: Official documents state that this medicine is indicated for the relief of involuntary muscle spasms in multiple areas. Its use is approved for spasms in the gastrointestinal (GI) and genitourinary (GU) tracts.

This means it is used to help with symptoms of conditions such as Irritable Bowel Syndrome (IBS) and colic.


Q: How quickly does Scopinal usually start working after taking it?

A: Clinical information indicates that after taking the oral tablet form, patients may begin to experience relief from painful cramps relatively quickly.

Symptoms are often indicated to start to ease within approximately 15 minutes.


Q: Are there any long-term side effects reported for Scopinal?

A: Official product information describes this medicine for short-term use. The regulatory guidance describes the drug as not being intended for continuous daily use or for extended periods.

If persistent symptoms require long-term use, regulatory documents require that the underlying cause be investigated by a healthcare professional.


Q: Is it common to feel tired or drowsy when taking Scopinal?

A: Adverse reaction reports indicate that the medicine may cause side effects such as dizziness or drowsiness (somnolence). While sleepiness is generally reported as uncommon, official warnings describe caution regarding driving or operating machinery if these effects occur.


Q: Is Scopinal safe to use if I have kidney problems?

A: Caution is officially advised when using this medicine in patients with impaired renal (kidney) function. This is because the drug is substantially excreted by the kidney.

In these situations, the risk of adverse reactions may be greater.


Q: Can older adults (seniors) use Scopinal?

A: Clinical data from trials that included patients aged 65 and older did not identify adverse reactions unique to this group. However, regulatory documents advise that dosage decisions for seniors are often handled cautiously. This caution reflects the increased likelihood of reduced organ function in older age groups.


Q: How long does the effect of one dose of Scopinal typically last?

A: According to the official pharmacological studies, the clinical effect of a single dose typically lasts for a specified duration.

The duration of relief is generally indicated to be approximately 4 to 6 hours.


Q: Is Scopinal an opioid or considered addictive?

A: Official regulatory assessments confirm that this drug is not an opioid. It is chemically classified as an anticholinergic agent.

Since the medicine is not centrally active in the brain, regulatory reviews suggest a low potential for abuse or dependence.


Q: Is Scopinal available without a prescription in some countries?

A: The active ingredient, Hyoscine Butylbromide, is included on the World Health Organization’s List of Essential Medicines.

Depending on the country's local regulations, the medicine may be available both over-the-counter (OTC) and by prescription.


Q: What if I take too much Scopinal by accident?

A: Official safety documents indicate that taking too much of the medicine can lead to a condition known as anticholinergic syndrome.

The severe effects of this syndrome include a fast heart rate (tachycardia) and disturbances in vision. Management typically focuses on treating these effects.


Q: Are there generic versions of Scopinal available?

A: Yes, the active ingredient in Scopinal is Hyoscine Butylbromide. This name is the non-proprietary or generic name for the compound.

Various manufacturers produce and sell the drug under different brand names globally.


Q: What does the term 'contraindication' mean for Scopinal?

A: The official drug labeling uses the term 'contraindication' to list specific situations where the medicine must not be used.

A contraindication describes situations where using the medicine is not permitted by official guidance, as the risk of serious harm or adverse effects, such as worsening untreated narrow-angle glaucoma, outweighs any possible benefit.


Q: Can I use Scopinal if I am planning a pregnancy?

A: Official regulatory guidance does not recommend use during pregnancy. This restriction is due to limited or insufficient human data establishing safety, and is classified as a precautionary measure.

Furthermore, studies on the effects on human fertility have not been conducted.


Q: Is it normal to have mild stomach upset when starting Scopinal?

A: Nausea, which can include stomach upset, is listed among the possible adverse effects in the official profile.

Some clinical study protocols specified that administering the treatment with food was done to investigate if it helped minimize the risk of gastrointestinal upset.


Q: Can Scopinal cause changes in mood or sleep patterns?

A: The drug's chemical design ensures it acts mainly in the body's periphery, which is intended to minimize effects on the central nervous system (CNS) like changes in mood.

However, anticholinergic effects such as dizziness and somnolence (sleepiness) are noted as possible adverse reactions.


Q: What is the difference between an allergy and a side effect to Scopinal?

A: Side effects are the possible, often mild, adverse reactions listed in the product information, such as dry mouth or constipation.

In contrast, an allergy (hypersensitivity reaction) is a rare but severe immune system response to the drug, which can include serious reactions like anaphylactic shock.


Q: Why do some people say Scopinal didn't work for them?

A: Clinical information indicates that results for similar treatments can vary widely depending on the patient and the condition being treated.

This variation, based on factors like treatment duration and patient-specific circumstances, can lead to different subjective experiences regarding the medicine’s efficacy.


Q: Why does the packaging of Scopinal mention special handling instructions?

A: Special instructions on packaging, such as keeping the medicine protected from light or moisture, are requirements from regulatory bodies.

These requirements are put in place to ensure that the medication maintains its chemical stability and full effectiveness until the expiry date.


Q: Can Scopinal be taken with common pain relievers like paracetamol or ibuprofen?

A: Official drug interaction information for this medicine and common pain relievers like paracetamol or ibuprofen is not generally reported as a known interaction in safety databases.

However, because drug profiles can change, patient monitoring is a required constraint when combining certain medications.

How should Scopinal be stored and disposed of?

The official requirements for storing and disposing of Scopinal (Hyoscine Butylbromide) are defined to maintain the product's stability and prevent harm.

Storage Requirements

Condition Regulatory Rule
Temperature Store below 30 C; room temperature is generally accepted [1].
Protection Keep protected from light and moisture; do not store in the bathroom or on a windowsill [1, 2].
Container Tablets should remain in their original pack [2]. Injection ampoules are for single use only [3].

Disposal and Safety

  • Child Safety: The medication must be kept out of the sight and reach of children [2, 3].
  • Unused Product: The contents of opened ampoules must be immediately discarded [3].
  • General Disposal: Do not throw away medicines via wastewater or household waste. Unused or expired products must be disposed of in accordance with local regulations, often by returning them to a pharmacy [4].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Scopinal found in:

A-Z Index: